tbuckley/cabot-search huggingface dataset:
Abstract 4092: Initial Experience with Subxiphoid Percutaneous Epicardial Ventricular Tachycardia Ablation in Patients with Prior Cardiac Surgery
Authors: Srijoy Mahapatra, George M McDaniel, Pamela K Mason, Gorav Ailawadi
Journal: Circulation (2008)

Introduction: Epicardial ablation via subxiphoid percutaenous access improves VT ablation success rate and is growing in popularity. However, it is unclear if this technique is feasible in patients with prior cardiac surgery because of pericardial adhesions. We describe results in our initial 12 patients with previous cardiac surgery. Methods: A total of 27 patients (11 women) underwent an epicardial VT ablation after failed antiarrhythmic drug therapy and at least one endocardial ablation. Twelve patients had undergone previous cardiac surgery (7 CABG, 3 valve only, 2 combined). The pericardium was accessed using a Tuohy needle. Then a guidewire and an irrigated tip catheter were used to free up adhesions. VT was mapped and ablated. We compared the results in patients with and without prior surgery. Results: There was no difference in the age (62±11 vs 58±13 years, p=ns), percent women (41 vs 40%, p=ns), EF (30±9 vs 27±11, p=ns), NYHA class (2.4±1.0 vs 2.1±0.9, p=ns) or use of beta-blockers (100 vs 93%, p=ns) or ACE inhibtors (100 vs 93%, p=ns) among patients with and without prior cardiac surgery. However, patients with prior surgery were more likely to have CAD (100 vs 66% p=0.02) and be on ASA (100 vs 73%, p=0.04.) The mean procedure (298±90 vs 178±45 min, p=0.01) and fluoroscopy time (106±24 vs 45±11 min, p=0.01) was longer in patients with prior surgery versus without surgery. The entire epicardium was mapped in 15/15 (100%) of the nonsurgical patients but only in 7/11 (64%) of the surgical patients due to adhesions (p=0.02.) The acute success rate, defined as elimination of all clinical VTs, was lower in the surgical group (75 vs 100%, p=0.02). Elimination of all VTs was achieved less often in post-surgical patient than non-surgical patients (58 vs 80%, p=0.04.) There were two occurrences of RV perforation in each group both treated with conservative therapy. There were no other complications. After 7±2 months, 66% of surgical patients and 80% of non-surgical patients were VT free (p=0.04) as monitored by ICD or 1, 3, and 6 month monitor. One patient in non-surgical group died of heart failure. Conclusion: Prior cardiac surgery does not preclude epicardial VT ablation but is associated with longer procedure times and lower success rates.
Abstract 13205: Everolimus Induces Human Leukocyte Antigen-G Expression In Human Coronary Artery Smooth Muscle Cells: Impact on Graft Rejection and Cardiac Allograft Vasculopathy
Authors: Amelia G Mociornita, Laura Tumiati, Jemy M Joseph, Liza Grosman-Rimon, Heather J Ross, Diego H Delgado, Rao Vivek
Journal: Circulation (2011)

Background:  Human leukocyte antigen-G (HLA-G) is a non-classical MHC I protein that plays an important role in immune tolerance. Its expression in serum and endomyocardial biopsies of heart transplant patients is associated with a lower incidence of graft rejection and cardiac allograft vasculopathy (CAV). However, the mechanisms of HLA-G expression remain vague. Previous clinical studies found that patients treated with everolimus expressed significantly higher levels of HLA-G in the blood plasma. Our objective was to determine if everolimus up-regulates HLA-G in human coronary artery smooth muscle cells (HCASMC), explaining a potential mechanism of HLA-G expression after heart transplant. We also tested if the soluble HLA-G inhibits HCASMC proliferation, a main cause of intimal hyperplasia associated with CAV.   Methods:  Commercially available HCASMC (n=6) were cultured in media containing 5% fetal bovine serum. After reaching full confluence the cells were exposed to various doses of everolimus (0.1-1000 ng/ml) for 24 hours. HLA-G expression was assessed by Western blot. We also cultured HCASMC (n=6) in conditioned media from Jeg-3 cells, choriocarcinoma cells known to release soluble HLA-G. Cell proliferation was measured at various time points (24-120 hours) post treatment.   Results:  There was a significant dose-dependent increase in HLA-G expression in the cells treated with 1000ng/ml of everolimus when compared to the control group (p=.005). Interestingly, there was no significant difference in proliferation between the cells treated with HLA-G conditioned media and the control group.   Conclusion:  We have shown for the first time that everolimus induces HLA-G expression in HCASMC in a dose-dependent manner. We have also shown that soluble HLA-G does not inhibit HCASMC proliferation in an in-vitro setting. Induction of HLA-G expression in HCASMC may represent a promising and novel therapeutic strategy to protect against graft rejection after heart transplantation. Although higher HLA-G levels protect against graft rejection, our results suggest that HLA-G does not inhibit SMC proliferation, implying that other cellular pathways may play a role in reducing CAV formation post transplant.
P0655 : Lamivudine prophylaxis prevents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non-Hodgkin's B cell lymphoma
Authors: M. Viganò, G. Grossi, E. Borsotti, M. Cappelletti, M. Goldaniga, L. Farina, M. Rumi, P. Corradini, L Baldini, M. Colombo, P. Lampertico
Journal: Journal of Hepatology (2015)
Abstract 9011: Randomized Study of Endovascular versus Epicardial Lead Placement for Resynchronization Therapy (REVERT)
Authors: Jonathan S Steinberg, Naga V Garikipati, Farooq Chaudhry, Praveena Paruchuri, Mehul Adhaduk, Khushbu Upadhyay, Mohan Nutheti, Ganesh Kamath, Rajeev Joshi, Edgar Argulian, Joseph J DeRose, Sandhya Balaram, Daniel Swistel, Suneet Mittal
Journal: Circulation (2011)

Introduction: Cardiac resynchronization therapy (CRT) is used to treat heart failure (HF) with prolonged QRS, with the LV lead typically placed transvenously (TV). Because CRT benefit correlates with concordant placement of the LV lead at the site of latest contraction, we hypothesized that epicardial (EPI) lead placement using a (robotic) surgical approach would afford more consistent access to the optimal site and result in improved clinical outcomes. The REVERT trial is the first prospective randomized clinical trial comparing EPI to TV lead placement for CRT. Methods: Twenty six pts (67.7 ± 8.7 yrs; EF 21.8 ± 8.2 %; QRS 159.5 ± 14 ms) with NYHA class III/IV HF were randomized to an EPI (n=12) or TV (n=14) LV lead implantation guided by preoperative echo dyssynchrony studies. Pts in both groups had similar baseline characteristics. Results: Compared to TV pts, EPI pts were slightly more likely to have LV lead placed concordantly (91% vs 71%, p= 0.34). However, the primary endpoint of LV end systolic volume index at 12 mos improved similarly in each group (Figure). There was also no difference in 2° endpoints at 12 mos (Table). Conclusions: In this randomized trial of primary CRT implantation, EPI LV lead placement, despite high concordancy, did not result in improved clinical outcomes vs TV lead placement.
Abstract 12768: Ultrasonic Tissue Characterization of Carotid Artery Plaque using High-resolution Integrated Backscatter Imaging: Validation Study with Histological Correlation
Authors: Mika Bando, Hirotsugu Yamada, Susumu Nishio, Etsuko Uematsu, Shuji Hayashi, Junko Hotchi, Kenya Kusunose, Noriko Tomita, Rina Tamai, Yukina Hirata, Daichi Hirota, Maya Nakagawa, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masataka Sata
Journal: Circulation (2011)
Abstract 317: Effect of Intra-arrest Induction of Therapeutic Hypothermia on Out-of-Hospital Cardiac Arrest
Authors: John Freese, Jeffrey Rabrich, Mark Menegus, Todd Slesinger, Robert Silverman, Norma Keller, Judy Dillworth, Doug Isaacs, David Ben-Eli, Pamela Lai, Glenn Asaeda, David Prezant
Journal: Circulation (2014)

Introduction: The resuscitation literature has recently suggested that the prehospital initiation of therapeutic hypothermia following successful resuscitation does not alter outcomes among patients who suffer sudden out-of-hospital cardiac arrest (OOHCA). We sought to assess the impact of earlier, intra-arrest induction of therapeutic hypothermia on OOHCA survival. Methodology: Out-of-hospital cardiac arrest data from two consecutive twelve-month periods was analyzed: August 1, 2009 - July 31, 2010 (Phase I), August 1, 2010 - July 31, 2011 (Phase II). In Phase I, paramedics in this urban system transported OOHCA patient to participating Cardiac Arrest Centers where the use of therapeutic hypothermia had been incorporated to the standard post-resuscitation care pathway. In Phase II, paramedics initiated hypothermia during the initial resuscitation effort through the rapid infusion of large-volume, ice-cold saline. Consistent with the Utstein definitions, analyses utilized only those cases which were bystander witnessed and of cardiac etiology. Results: There were 1,487 and 850 bystander witnessed arrests of cardiac etiology in the two phases. Patient and arrest characteristics for the two groups did not differ with respect to age, gender, race, response time, bystander witnessed status, or the frequency of bystander CPR. Return of spontaneous circulation (ROSC), sustained ROSC, survival to hospital admission and survival to hospital discharge did not differ significantly from Phase I to Phase II: 40.82% vs 39.59% (p=.54), 31.10% vs 31.17% (p=0.58), 27.15% vs 24.88% (p=0.27), and 6.62% vs 6.19% (p=0.41). In addition, among those survivors for whom neurologic status is known, the intra-arrest initiation of therapeutic hypothermia did not significantly change the proportion of survivors considered neurologically intact (76.47% vs 70.37%, all p=0.59). Conclusions: The intra-arrest initiation of therapeutic hypothermia did not alter outcomes among OOHCA patients, demonstrating neither harm nor benefit. Whether this is due to a lack of continuation of hypothermia following hospital admission or a true lack of benefit requires further collaborative work between the prehospital and hospital communities.
Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial
Authors: Susan O'Brien, Jeffrey A. Jones, Steven Coutre, Anthony R. Mato, Peter Hillmen, Constantine Tam, Anders Osterborg, Tanya Siddiqi, Michael J. Thirman, Richard R. Furman, Osman Ilhan, Michael Keating, Timothy G. Call, Jennifer R. Brown, Michelle Stevens-Brogan, Yunfeng Li, Maria Fardis, Fong Clow, Danelle F. James, Alvina D. Chu, Michael Hallek, Stephan Stilgenbauer
Journal: Blood (2014)
Simple Apparatus for the Simultaneous Monitoring of Central Venous and Mean Arterial Pressures in the Ward
Authors: B. J. Aarons
Journal: Thorax (1965)

The apparatus described is used for the monitoring of venous and arterial pressures after open heart surgery and provides a means of administer- ing drugs intravenously and of taking samples of venous or arterial blood.It has now been used on 70 consecutive cases for periods varying from one to 72 hours (average 20 hours) without any complications.The design is simple and the
Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction
Authors: Gregg W Stone, E.Magnus Ohman, Michael F Miller, Debra L Joseph, Jan T Christenson, Marc Cohen, Philip M Urban, Ramachandra C Reddy, Robert J Freedman, Karen L Staman, James J Ferguson
Journal: Journal of the American College of Cardiology (2003)
Abstract 10745: Dobutamine Stress Echocardiography Predicts Cardiac Events but Not Total Mortality In Octogenarian Patients Referred with Suspected Cardiac Chest Pain
Authors: Jamie O'Driscoll, Katharina Schmid, Anna Marciniak, Ansuman Saha, Robert Smith, Sanjay Gupta, Rajan Sharma
Journal: Circulation (2011)

Background - The prognostic significance of dobutamine stress echocardiography (DSE) in octogenarians remains unclear despite increasing referrals. This study aimed to investigate whether DSE predicts total mortality and cardiac events in octogenarians. Methods - Five hundred and fifty consecutive octogenarians (mean age 84 ± 3.7 years) with suspected cardiac chest pain had DSE. A positive result was defined as a new or worsening wall motion score in 1 or more left ventricular (LV) segments. Demographic, baseline, and peak DSE data were collected. Total mortality and cardiac events (cardiac mortality and non-fatal myocardial infarction) were prospectively analyzed. Results - DSE was successfully completed in all patients with no adverse outcomes. One hundred and eighty three (33%) patients had a positive DSE result, 271 (49%) had a normal study, and 96 (18%) had fixed wall motion abnormalities. During a mean follow up of 2.1 ± 1.1 years, there were 217 (40%) cardiac events and 63 (12%) deaths, of which 46...
Abstract 13947: Cardiac Resynchronization Therapy Prevents Progression of Renal Failure in Heart Failure Patients
Authors: Vinodh Jeevanantham, David Shanberg, Andre Saad, Basil Abu-El-Haija, Buddhadeb Dawn, Dhanunjaya Lakkireddy
Journal: Circulation (2011)

Introduction The effect of cardiac resynchronization therapy (CRT) on renal function in patients with heart failure is not well understood. We hypothesized that response to CRT would prevent worsen...
Abstract 5538: Apoptosis Signal-Regulating Kinase (ASK) 2 Deficient Mice Have Salt-Resistant Hypertension With Cardiac Hypertrophy
Authors: Keiichiro Kataoka, Taishi Nakamura, Masaya Fukuda, Hisato Nako, Yi fei Dong, Rei Liu, Yoshiko Tokutomi, Hisao Ogawa, Shokei Mitsuyama
Journal: Circulation (2009)

Background: Apoptosis signal-regulating kinase (ASK) 2 is a MAP3K that is highly related to ASK1. ASK2 is activated in response to oxidative stress. There have been no reports about the cardiovascular functions of ASK2. Herein, we show the cardiovascular phenotypes of ASK2 deficient mice (ASK2KO). Methods and Results: ASK2KO had higher blood pressures than wild type mice (WT) (122±1 vs. 104±0.4 mmHg, p&lt;0.01). Urinary catecholamine excretion in ASK2KO was significantly increased compared to WT, indicating that hypertension in ASK2KO is associated with enhanced sympathetic nerve activity. Histological examinations revealed that myocardial fibrosis was increased in ASK2KO compared to WT. The number of macrophages and superoxide levels were greater in ASK2KO than in WT. ASK2KO were administered either olmesartan or hydralazine in order to determine if myocardial fibrosis in ASK2KO is associated with the renin-angiotensin system (RAS). Although blood pressures of both groups were decreased to the same levels as normal WT levels, only the olmesartan group had both decreased myocardial fibrosis and inflammatory cell infiltration; this indicates that cardiac hypertrophy in ASK2KO is associated with RAS. ASK2KO and WT were fed a high salt diet (8% NaCl) to examine whether hypertension in ASK2KO is salt-sensitive or not. Blood pressures of ASK2KO were significantly decreased by salt loading, although those of WT were not. Increased cardiac fibrosis and inflammatory cell infiltration observed in normal diet ASK2KO were also significantly decreased by salt loading. This shows that hypertension and cardiac hypertrophy in ASK2KO are salt resistant. Salt loading increased ASK2 mRNA in the heart tissues of WT, and it enhanced the inflammatory responses, oxidative stress and TGFβ expression in WT hearts, but these effects were not observed in ASK2KO, which indicates that ASK2 is involved in salt induced cardiac injury. Conclusions: ASK2KO have salt-resistant hypertension with cardiac hypertrophy. ASK2 plays an important role in blood pressure regulation and cardiac hypertrophy in association with RAS. ASK2 plays a pivotal role in salt-induced cardiac injuries in association with oxidative stress and inflammatory responses.
Prolonged Lymphocytepenia after Bendamustine with or without Rituximab Treatment in Patients with Relapsed or Refractory Indolent B-Cell and Mantle Cell Lymphoma
Authors: Hideaki Saito, Dai Maruyama, Akiko Miyagi Maeshima, Shin-ichi Makita, Hideaki Kitahara, Ken-ichi Miyamoto, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Yukio Kobayashi, Hirokazu Taniguchi, Kensei Tobinai
Journal: Blood (2014)
Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)
Authors: Saikat Saha, Warren Fiskus, Sunil Sharma, Bhavin Shah, Anna T Rogojina, Santhana G. T. Devaraj, Baohua Sun, Christopher Leveque, Youli Zu, Swaminathan Padmanabhan Iyer, Kapil N. Bhalla
Journal: Blood (2014)
Abstract 18120: Variants of Toll Like Receptor 4 Have Prognostic Value in Patients with Dilated Cardiomyopathy
Authors: Alexander Riad, Henriette Meyer zu Schwabedissen, Kerstin Weitmann, Markus Grube, Marcus Dörr, Lars R Herda, Klaus Empen, Arne Kieback, Astrid Hummel, Reinhard Kandolf, Wolfgang Hoffmann, Heyo K Kroemer, Stephan B Felix
Journal: Circulation (2011)

Background - Dilated cardiomyopathy (DCM) may attend with innate immune activation, but its prognostic value is largely unknown. Since the innate immune Toll-like receptor 4 (TLR4) has been shown to be involved in atherosclerosis, we investigated the impact of coding polymorphisms of TLR4 on development and prognosis of DCM in patients. Methods and results - Two previously reported genetic variants of TLR4 (rs4986790, TLR4 c.1187A&gt;G, p.299D&gt;G and rs4986791,TLR4 c.1487C&gt;T, p.T399I) were investigated. Coronary artery disease and other reasons for heart failure were excluded by angiography, myocardial biopsy, two dimensional echocardiography and spirometry. There were no significant differences between genetically defined subgroups with respect to baseline risk factors, age, gender and treatment. Presence of the rs4986790 and/or the rs4986791 variant, respectively, was not associated with an increased incidence of DCM. In contrast, patients carrying both the rs4986790 and the rs4986791 variant showed significantly reduced improvement of left ventricular (LV) ejection fraction (P=0.006) and LV dilation (P=0.015) at the follow-up evaluation when compared to carriers of the wildtype gene and isolated rs4986790 or rs4986791 variants, respectively (Figure 1). This was associated with significantly reduced levels of nt-pro brain natriuretic peptide (BNP) in patients carrying the TLR4 wildtype gene and isolated TLR4 variants at the follow-up when compared to the first admissions evaluation. Carriers of both variants did not show a significant decrease of nt-pro BNP. Conclusion - Among patients with DCM, the common presence of the TLR4 variants rs4986790 and rs4986791 predict worsened LV ejection fraction, LV dilation and nt-pro BNP levels at the course of time.
Human Platelets and Factor XI
Authors: Myatt S. Lipscomb, Peter N. Walsh
Journal: Journal of Clinical Investigation (1979)

Because human platelets participate in the contact phase of intrinsic coagulation and contain a Factor XI-like coagulant activity, the nature of the Factor XI-like activity was examined and compared with purified plasma Factor XI. The platelet factor XI-like activity was sedimented with the particulate fraction of a platelet lysate, was inactivated by heat (t1/2 3.5 min, 56°C), was not a nonspecific phospholipid activity, and was destroyed by treatment with Triton X-100. Isolated platelet membranes were four-fold enriched in Factor XI activity and similarly enriched in plasma membrane marker enzymes. The Factor XI-like activity of platelet membranes was detected only when assayed in the presence of kaolin, which suggests that it is present in an unactivated form and can participate in contact activation. Concanavalin A inhibited the Factor XI-like activity of platelet lysates and platelet membranes but not of plasma or purified Factor XI. A platelet membrane-Factor XI complex was isolated after incubation of membranes with purified Factor XI. The Factor XI activity of the platelet membrane-plasma Factor XI complex was inhibited by concanavalin A, whereas unbound plasma Factor XI retained activity. An antibody raised against plasma Factor XI inhibited the in vitro Factor XI activity of plasma and of the platelet membrane-plasma Factor XI complex but had no effect on the endogenous Factor XI-like activity of washed lysed platelets or isolated platelet membranes. Washed platelets and isolated platelet membranes obtained from a Factor XI-deficient donor without a history of excessive bleeding had normal quantities of platelet Factor XI-like activity and normal behavior in the contact phase of coagulation (collagen-induced coagulant activity). These results indicate that platelet membranes contain an endogenous Factor XI-like activity that is functionally distinct from plasma Factor XI.
The Induction of Mild Hypothermia Prevents Sympathetic Activation but Preserves Systemic Vascular Resistance During Endotoxemia in Pigs
Authors: Michael Schwarzl, Sebastian Seiler, Stefan Huber, Paul Steendijk, Heinrich Machler, Martini Truschnig-Wilders, Burkert Pieske, Heiner Post
Journal: Circulation (2011)
Abstract 2434: Contractility Augmentation Induced by Refractory Period Stimulation Depends upon Pacing-Site and Diminishes Over Time
Authors: Richard Cornelussen, Robert Mills, Berthold Stegemann, Will Wodzig, Frits Prinzen
Journal: Circulation (2008)

Purpose : Refractory period stimulation (RPS) is proposed as a novel, clinically useful method to improve left (LV) and right ventricular (RV) contractility and might be attributed to local para-vascular sympathetic nerve stimulation. We hypothesize that during RPS contractility is largest during proximal (nerve) stimulation, is related to noradrenaline (NA) release and accompanied by disturbed relaxation. Methods : RPS was delivered with unipolar, epicardial leads on 3 locations (proximal (p), median (m) and distal (d)) along LAD, LCX, and RCA in open thorax, healthy canines (n=7). RPS consisted of 3 pulses (amplitude 8V, width 1.6 ms) at 40 ms interval, delivered ~40 ms after the R-wave. LV/RV pressures were measured. +dP/dt was used to quantify contractility and −dP/dt used to quantify relaxation. Each site was stimulated for 2 min followed by 5-min baseline. During prolonged RPS-delivery (60 min with 30 min recovery), coronary sinus NA was also measured. Results : The highest increase in LV+dP/dt was achieved during LADp stimulation (14±7% (mean±sem) increase vs baseline) and lowest during LADd stimulation (9±2%). Delivering RPS along the different LCX locations displayed similar increases in +dP/dt (LCXp; 6%±2%, LCXm; 8±2%, LCXd; 7±2%), but significantly less than the LAD-locations, thus pointing toward a nonuniform sympathetic nerve distribution in the LV wall. RPS at the 3 RCA sites had no effect on LV+dP/dt but greatly enhanced RV+dP/dt (RCAp; 21±6%, RCAm; 22±5%,RCAd; 15±5%, respectively), indicating the localized effect of RPS application. The degree of improvement in LV+dP/dt when using the LAD or LCX was accompanied by similar degree of impairment of LV relaxation (eg for LADp −dP/dt decreased by11±7%). During prolonged RPS delivery, the contractility augmentation significantly decreased from 12±5% to 6±2%. This was accompanied by a similar drop in NA-release into the coronary sinus from 1.08±0.38 to 0.47±0.06 nmol/l (baseline 0.24±0.07 nmol/l). Conclusion : RPS-induced increase in myocardial contractility depends on the ventricular localization, diminishes over time and most likely involves noradrenalin release from nerve endings. The depression in relaxation is presumably due to regional differences in adrenergic stimulation.
Abstract 21230: The Beneficial Effects of an Intense Combined Weight Loss Exercise and Diet Program on Cardiovascular Risk Factors and Inflammation - An Analysis From the Biggest Loser Program
Authors: Naser Ahmadi, Shervin Eshaghian, Robert Huizenga, Kira Sosnin, Ramin Ebrahimi, Robert Siegel
Journal: Circulation (2010)

Background: Obesity is associated with insulin resistance (IR), dyslipidemia, inflammation, cardiovascular risk factors, metabolic dysfunction, and coronary artery disease. This study investigates ...